Latest Advances in Lung Cancer Research

BAD LINK – see if the article is elsewhere

Lung cancer care disparities: An in depth analysis of racial disparity and inclusivity in lung cancer heath care, research, and community buidling.

Sotorasib drug shows meaningful benefits clincally with advanced KRAS G12C mutation in non-small cell lung cancer patients.

Lorlatinib approved for ALK-Positive NSCLC. The FDA expands approval of Lorlatinib for frontline treatment of ALK+ lung cancer patients.

Research shows using both immunotherapy and chemotherapy for treatment doubles survival among those diagnosed with lung cancer.

KRAS mutation, previously seen as “undruggable” sees promise for new therapies through improbable targets for lung cancer.

Patients with pretreated SCLC have improved outcomes. Apatinib combined with chemotherapy in patients with prior treatments indicate good efficacy/safety.

IASLC discusses lung cancer care and research disparities among socioeconomic, ethnic, racial, and gender-related groups.

Why are lung cancer deaths in non-smokers on the rise? The proportion of non-smoker lung cancer patients jumped from 8% in 1990 to 15% in 2013.

Tepotinib approved for MET+ NSCLC treatment. Specifically, approval for metastatic NSCLC with MET exon 14 skipping alterations.

Breast cancer tops lung cancer as most diagnosed cancer. Although breast cancer leads in cases, lung cancer leads in deaths.

Merck pulls Keytruda for SCLC. Pharmaceutical company, Merck announced plans to pull Ketruda for SCLC due to disappointing results from Phase III trial.